ArticleScientific reports2025
Current diagnostic and therapeutic management of chronic rhinosinusitis with nasal polyps in Austria: insights and unmet needs from a nationwide survey.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rethinking Monospecific Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps: Dual- and Multispecific Antibodies.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article aims to describe the current diagnostic and therapeutic practices for managing chronic rhinosinusitis with nasal polyps (CRSwNP) among Austrian ENT specialists. A cross-sectional, nationwide survey was conducted between November and December 2022 in Austria. A total of 50 ENT specialists, evenly split between hospital- and office-based physicians, participated. The questionnaire covered demographics, diagnostic and therapeutic approaches. CT imaging, nasal endoscopy, and blood eosinophil count were the most utilized diagnostic tools. Most participants applied the SNOT-22 for patient-reported outcomes. Local corticosteroids were the most frequently prescribed treatment. Systemic corticosteroid overuse and limited biologic adoption were noted. Hospital-based physicians managed significantly more patients with biologics. The initiation of biologic therapy was considered most appropriate following one FESS by the vast majority of respondents. Adherence to guideline-based evaluation criteria for biologic treatment response was suboptimal, highlighting gaps in clinical practice. Our survey highlights strengths in guideline adherence and areas for improvement, particularly in the diagnostic approach, systemic corticosteroid usage, and biologic treatment. Addressing educational gaps and refining clinical practices could enhance patient outcomes, reduce invasive procedures, and optimize resource utilization in CRSwNP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.